Smoking: Clinical Trials

158 trials for Smoking, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

158 completed. 158 Phase 2, 24 Phase 1, 21 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2158Completed 158
Phase 124Completed 24
Phase 321Completed 21

Follow Smoking: new trials by email Literature Review of Smoking trials Research Report on Smoking

Trials (filtered) newest first · largest first

All 158 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes
Regular Nicotine patch and lozenge dose, Augmented Nicotine patch and lozenge dose - Smoking Cessation, Electronic Cigarette Use
Phase 2CompletedMedical University of South Carolina462023-12-052025-11-26
Free Samples for Health
Ask-Advise-Refer, Nicotine Patch, 14 Mg/24 Hr Transdermal Film, Extended Release, Nicotine lozenge - Cigarette Smoking
Phase 2CompletedSandra Japuntich12392023-06-122026-07-24
Exenatide for Smoking Cessation and Prevention of Weight Gain
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch - Smoking Cessation, Weight Gain
Phase 2CompletedThe University of Texas Health Science Center, Houston1402022-12-072026-03-23
Transcranial Magnetic Stimulation in Smokers: an Examination of Mediating Neural Pathways.
Active repetitive Transcranial Magnetic Stimulation, Sham repetitive Transcranial Magnetic Stimulation - Smoking
Phase 2CompletedKent State University62022-11-082024-03-08
Varenicline for Treatment of E-cigarette Dependence
Varenicline Tartrate, Placebo - Smoking Cessation
Phase 2CompletedYale University402022-11-042024-12-02
Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes
Nicotine 0 mg/mL, Nicotine 6 mg/mL, Nicotine 12 mg/mL - Nicotine, E-liquid Flavors
Phase 2CompletedYale University542022-10-272024-08-05
Semaglutide for Alcohol Use Disorder
Semaglutide, Sham/placebo - Alcohol Use Disorder, Cigarette Smoking
Phase 2CompletedUniversity of North Carolina, Chapel Hill482022-09-022025-04-02
A Study of Cytisinicline for Vaping Cessation in Adult Smokers
cytisinicline, Placebo, Behavioral support - Vaping, E-Cig Use
Phase 2CompletedAchieve Life Sciences1602022-07-132026-01-14
Pulmonary and Cardiac Effects of E-Cigarette Use in Pulmonary Patients Who Smoke Cigarettes
E-Cigarette, Financial Incentives - Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Phase 2CompletedUniversity of Vermont212022-04-282024-02-08
Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors in Laos
Nicotine patch, Self-help materials (to support smoking cessation), Smartphone-based automated treatment for smoking cessation - Cigarette Smoking
Phase 2CompletedUniversity of Oklahoma802022-04-202024-08-28
Incentives for Oklahoma Tobacco Helpline Engagement in Persistent Poverty Counties
Coaching calls, Nicotine replacement therapy, Financial Incentives - Cigarette Smoking, Nicotine Dependence
Phase 2CompletedUniversity of Oklahoma1652022-03-092024-12-30
Heart Rate Variability Biofeedback for Smoking Cessation Treatment
Cognitive-Behavioral Smoking Cessation, Heart Rate Variability Biofeedback, Nicotine patch - Tobacco Smoking
Phase 2CompletedRutgers, The State University of New Jersey282021-11-292024-05-01
Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts
Nicoderm CQ 21Mg/24Hr Transdermal System - Tobacco Use Cessation
Phase 2 / Phase 3CompletedBrown University492021-09-012025-04-06
Proactive Outreach for Smoking Treatment
Study 3: Chronic care management, Study 2: Pilot trial - Smoking, Tobacco, Mental Illness
Phase 2CompletedSandra Japuntich942021-07-142025-12-08
Quit Smoking Study for People Who Use E-Cigarettes
Nicotine replacement therapy patch, Nicotine replacement therapy lozenge, Quit electronic cigarettes - Nicotine Addiction, E-Cig Use
Phase 2CompletedUniversity of Vermont3962021-06-272025-05-22
The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence
E-cigarettes - Nicotine Dependence
Phase 1 / Phase 2CompletedDuke University202021-05-212024-02-21
STARS (Smoking Treatment And Remote Sampling) Study
Varenicline 0.5 MG, Nicotine Replacement Therapy (NRT) - Smoking, Smoking Cessation
Phase 1 / Phase 2CompletedMedical University of South Carolina6522021-02-082026-02-17
E-cigarette Nicotine Study
Nicotine, Juul e-cigarette, Reduction - Nicotine Dependence, Electronic Cigarette Use
Phase 2CompletedUniversity of Vermont772021-01-202022-08-26
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
E cigarettes, Nicotine Replacement Therapy - Cigarette Smoking, Addiction
Phase 2CompletedNYU Langone Health482020-10-272024-12-20
Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g), E-Cigarettes - Tobacco Use Disorder
Phase 2CompletedBrown University3262020-10-182025-04-01

Showing 20 of 158. Sign in to see all of them.

Narrower conditions

Smoking Cessation (52)  ·  Tobacco Use Disorder (50)  ·  Cigarette Smoking (45)  ·  Vaping (12)  ·  Alcoholism (8)  ·  Marijuana Smoking (7)  ·  Schizophrenia (7)  ·  Tobacco Smoking (6)  ·  Tobacco Use Cessation (6)  ·  Alcohol Drinking (5)  ·  Asthma (4)  ·  Behavior, Addictive (4)  ·  Body Weight (4)  ·  Pulmonary Disease, Chronic Obstructive (4)

Broader conditions

Behavior (158)  ·  Mental Disorders (75)  ·  Chemically-Induced Disorders (61)  ·  Substance-Related Disorders (60)  ·  Health Behavior (58)  ·  Tobacco Use (48)  ·  Tobacco Smoking (43)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Lung Diseases (10)  ·  Respiratory Tract Diseases (10)  ·  Smoking, Non-Tobacco Products (8)  ·  Alcohol-Related Disorders (7)  ·  Pathologic Processes (7)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (7)

Interventions

Varenicline (24)  ·  Tobacco Use Cessation Devices (22)  ·  Nicotine (17)  ·  Nicotine Replacement Therapy (12)  ·  Bupropion (11)  ·  Electronic Nicotine Delivery Systems (7)  ·  Naltrexone (7)  ·  Nicotine Chewing Gum (5)  ·  Behavior Therapy (4)  ·  Cognitive Behavioral Therapy (4)  ·  Counseling (4)  ·  Sugars (4)  ·  Dronabinol (3)  ·  Ethanol (3)  ·  Mecamylamine (3)

Sponsors

Yale University (20)  ·  Mayo Clinic (9)  ·  Brown University (7)  ·  Duke University (6)  ·  Medical University of South Carolina (5)  ·  National Institute on Drug Abuse (NIDA) (5)  ·  University of Pennsylvania (4)  ·  University of Vermont (4)  ·  National Cancer Institute (NCI) (3)  ·  The University of Texas Health Science Center, Houston (3)  ·  University of Minnesota (3)  ·  Centre for Addiction and Mental Health (2)  ·  GlaxoSmithKline (2)  ·  Johns Hopkins University (2)  ·  Maastricht University Medical Center (2)

Countries

United States (131)  ·  Canada (3)  ·  Brazil (2)  ·  Denmark (2)  ·  France (2)  ·  Israel (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Australia (1)  ·  Czechia (1)  ·  Egypt (1)  ·  Finland (1)  ·  Hungary (1)  ·  India (1)

Top investigators

Sherry A McKee, PhD (4)  ·  Jed E Rose, Ph.D. (3)  ·  Jed E. Rose, Ph.D. (2)  ·  Laura MacPherson, PhD (2)  ·  Luba Yammine, PhD (2)  ·  Stephanie O'Malley, PhD (2)  ·  Suchitra Krishnan-Sarin, Ph.D. (2)  ·  Allan V. Prochazka, MD MSc (1)  ·  Allen Zweben, PhD (1)  ·  Amanda Palmer (1)  ·  Amit Sood, M.D., MSc (1)  ·  Amit Sood, MD (1)  ·  Andrea C King, PhD (1)  ·  Andrew Strasser, MBBS, PhD (1)

Results publications

PMID 37142273, PMID 37230961, PMID 29663982, PMID 34611902, PMID 39240566, PMID 42560883, PMID 15534159, PMID 16240558, PMID 17587504, PMID 18480694, PMID 18686184, PMID 19196814, PMID 19483180, PMID 19524389, PMID 20056957, PMID 20078491, PMID 20081039, PMID 20191360, PMID 20334673, PMID 20434863, PMID 20466951, PMID 20542391, PMID 20590478, PMID 20719253, PMID 20947286, PMID 21163939, PMID 21221531, PMID 21270788, PMID 21276244, PMID 21356232, PMID 21473764, PMID 21652735, PMID 21928117, PMID 22007015, PMID 22097928, PMID 22157229, PMID 22229310, PMID 22352784, PMID 22592966, PMID 22741619, PMID 22761006, PMID 22898118, PMID 22993168, PMID 23177384, PMID 23216646, PMID 23265707, PMID 23282113, PMID 23536105, PMID 24399554, PMID 24894625

NIH funding

P50AA015632 (5), P50DA027840 (4), P50DA033945 (3), U54DA036114 (3), P50DA013333 (2), R34DA043751 (2), 2004 (1), 2014 (1), K01DA019446 (1), K01MD015295 (1), K23DA022471 (1), K23DA039294 (1), N01CN35159 (1), P01AA027473 (1), P30CA068485 (1)